NCT02742194

Brief Summary

Regarding its complex pathogenesis and clinic-epidemiological meaning, different strategies are needed for the treatment of obesity. Ginger is the rhizome of a plant with thermogenic and anti-inflammatory effects, and may be a promising alternative as add-on strategy in the treatment for obesity. The primary objective of the current study is to assess whether consumption of ginger as an add-on strategy to restrictive diet is effective to reduce fat body percentage, increase basal metabolic rate and improve loss weight. The secondary objectives are:

  • to assess the effect of nutritional intervention in quality of diet and weight loss.
  • to evaluate the effect of ginger on behavioral symptoms and peripheral biomarkers in overweight subjects.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
84

participants targeted

Target at P25-P50 for phase_2 obesity

Timeline
Completed

Started Aug 2015

Typical duration for phase_2 obesity

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2015

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

February 5, 2016

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 18, 2016

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2018

Completed
Last Updated

April 18, 2016

Status Verified

April 1, 2016

Enrollment Period

3.3 years

First QC Date

February 5, 2016

Last Update Submit

April 13, 2016

Conditions

Keywords

ginger obesityginger inflammationtreatment of obesity

Outcome Measures

Primary Outcomes (2)

  • Change in basal metabolic rate.

    Ginger effect in basal metabolic rate will be measured by calorimetry.

    Baseline and 30, 60, 90, 120, 150 and 180 days

  • Change in body fat percentage.

    Ginger effect in body fat percentage will be measured by bioimpedance.

    Baseline and 30, 60, 90, 120, 150 and 180 days

Secondary Outcomes (7)

  • Changes in serum levels of inflammatory mediators

    Baseline and 30, 60, 90, 120, 150 and 180 days

  • Change in depressive symptoms.

    Baseline and 30, 60, 90, 120, 150 and 180 days

  • Change in anxiety symptoms.

    Baseline and 30, 60, 90, 120, 150 and 180 days

  • Change in quality of life.

    Baseline and 30, 60, 90, 120, 150 and 180 days

  • Change in perceived stress.

    Baseline and 30, 60, 90, 120, 150 and 180 days

  • +2 more secondary outcomes

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Conventional treatment (restrictive diet) plus capsules of 200 mg of cellulose (placebo) to be taken three times a day for six months.

Dietary Supplement: Placebo

Ginger group

EXPERIMENTAL

Conventional treatment (restrictive diet) plus capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.

Dietary Supplement: Dry extract of ginger

Interventions

Dry extract of gingerDIETARY_SUPPLEMENT

Restrictive diet plus three capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.

Ginger group
PlaceboDIETARY_SUPPLEMENT

Restrictive diet plus three capsules of 200 mg of cellulose to be taken three times a day for six months.

Placebo

Eligibility Criteria

Age18 Years - 60 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Women aged 18-60 years old;
  • Body mass index 25-35 kg/m².

You may not qualify if:

  • Pregnant or lactating women;
  • Abuse of alcohol or drugs;
  • Hypersensitivity to ginger;
  • Other endocrine disease;
  • Women in use of insulin or anti-inflammatory and antidepressants drugs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital das Clínicas

Belo Horizonte, Minas Gerais, 30130-100, Brazil

RECRUITING

Related Publications (5)

  • van Reedt Dortland AK, Giltay EJ, van Veen T, Zitman FG, Penninx BW. Longitudinal relationship of depressive and anxiety symptoms with dyslipidemia and abdominal obesity. Psychosom Med. 2013 Jan;75(1):83-9. doi: 10.1097/PSY.0b013e318274d30f. Epub 2012 Nov 28.

    PMID: 23197842BACKGROUND
  • Atashak S, Peeri M, Azarbayjani MA, Stannard SR, Haghighi MM. Obesity-related cardiovascular risk factors after long- term resistance training and ginger supplementation. J Sports Sci Med. 2011 Dec 1;10(4):685-91. eCollection 2011.

    PMID: 24149559BACKGROUND
  • Chrubasik S, Pittler MH, Roufogalis BD. Zingiberis rhizoma: a comprehensive review on the ginger effect and efficacy profiles. Phytomedicine. 2005 Sep;12(9):684-701. doi: 10.1016/j.phymed.2004.07.009.

    PMID: 16194058BACKGROUND
  • Gregersen NT, Belza A, Jensen MG, Ritz C, Bitz C, Hels O, Frandsen E, Mela DJ, Astrup A. Acute effects of mustard, horseradish, black pepper and ginger on energy expenditure, appetite, ad libitum energy intake and energy balance in human subjects. Br J Nutr. 2013 Feb 14;109(3):556-63. doi: 10.1017/S0007114512001201. Epub 2012 Jul 5.

    PMID: 23021155BACKGROUND
  • Saravanan G, Ponmurugan P, Deepa MA, Senthilkumar B. Anti-obesity action of gingerol: effect on lipid profile, insulin, leptin, amylase and lipase in male obese rats induced by a high-fat diet. J Sci Food Agric. 2014 Nov;94(14):2972-7. doi: 10.1002/jsfa.6642. Epub 2014 Apr 7.

    PMID: 24615565BACKGROUND

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Adaliene VM Ferreira, PhD

    Federal University of Minas Gerais

    STUDY DIRECTOR
  • Nayara M Monteze, Ma

    Federal University of Minas Gerais

    STUDY CHAIR
  • Antônio L Teixeira, PhD

    Federal University of Minas Gerais

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Antônio L Teixeira, PhD

CONTACT

Antônio L Teixeira, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

February 5, 2016

First Posted

April 18, 2016

Study Start

August 1, 2015

Primary Completion

November 1, 2018

Study Completion

November 1, 2018

Last Updated

April 18, 2016

Record last verified: 2016-04

Data Sharing

IPD Sharing
Will not share

Locations